ABBV250103P230000
- 0.00
- 0.000.00%
AbbVie Newsroom
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Announces Target Price $211
Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)
AbbVie Price Target Lowered to $211 From $215 at Truist
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
AbbVie (ABBV) Stock Moves -0.32%: What You Should Know
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Express News | Capsida - Eligible for Additional Milestones and Royalties
Express News | Capsida - Co to Receive $40 Million License Payment
Express News | Capsida Announces Abbvie Opt-in for First Genetic Medicine Program From Neurodegenerative Disease Collaboration
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program From Neurodegenerative Disease Collaboration
CoolMonth Is Back With Deals on CoolSculpting Elite by Allergan Aesthetics
AbbVie Cuts 2024 Profit Forecast on Acquisition Expenses
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06
Express News | Abbvie Inc Q4 Shr View $2.98 -- LSEG IBES Data
Express News | Abbvie Inc - Q4 2024 Adj EPS Guidance Range $2.06 - $2.10